While behavioral interventions remain the mainstay of treatment of autism spectrum disorder
(ASD), several potential targeted treatments addressing the underlying neurophysiology of …

Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive
and behavioural deficits and represent a major public health burden. FXS is the most …

To date, no medication is proven to be effective in treating core symptoms of autism
spectrum disorder (ASD). Psychotropic medications are widely used to target emotional and …

The goal of this study was to determine whether a phosphodiesterase-4D (PDE4D) allosteric
inhibitor (BPN14770) would improve cognitive function and behavioral outcomes in patients …

Fragile X syndrome (FXS) is a neurodevelopmental disorder caused by the full mutation as
well as highly localized methylation of the fragile X mental retardation 1 (FMR1) gene on the …

Fragile X syndrome (FXS) is the leading inherited form of intellectual disability and autism
spectrum disorder, and patients can present with severe behavioural alterations, including …

Positive, prosocial interactions are essential for survival, development, and well-being.
These intricate and complex behaviors are mediated by an amalgamation of neural circuit …

Background There has been recent systematic review of key evidence in psychosocial
intervention in autism but little review of biological treatments. Methods We analyse the …

With the recent 50th anniversary of the first publication on Rett syndrome, and the almost 20
years since the first report on the link between Rett syndrome and MECP2 mutations, it is …

Mutations in the phosphatase and tensin homolog (PTEN) gene are associated with severe
neurodevelopmental disorders. Loss of PTEN leads to hyperactivation of the mechanistic …